Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Harsh Dua"'
Publikováno v:
Apollo Medicine, Vol 16, Iss 1, Pp 58-60 (2019)
Primary thyroid lymphoma is a rare neoplasm consisting of 1%–5% of all thyroid neoplasms. These are predominantly B-cell in origin. It is curable without surgery. The literature search shows it to be presenting as rapidly developing thyroid mass. I
Externí odkaz:
https://doaj.org/article/ccea6168a5aa45efb24cda882cd117dc
Publikováno v:
Lung India, Vol 33, Iss 6, Pp 653-656 (2016)
The tracheobronchial origin of non-Hodgkin's lymphoma (NHL) is a very rare presentation, and there are only a few case reports of primary tracheal or endobronchial NHL. We have two cases of primary tracheobronchial NHL; one case was incidentally diag
Externí odkaz:
https://doaj.org/article/64cfb17215634501b47ea737e0d86848
Autor:
R N Makroo, Mohit Chowdhry, Manoj Kumar, Priyanka Srivastava, Richa Tyagi, Preeti Bhadauria, Sumaid Kaul, Ramesh Sarin, P K Das, Harsh Dua
Publikováno v:
Indian Journal of Pathology and Microbiology, Vol 55, Iss 4, Pp 481-484 (2012)
Background : In India, the incidence of breast cancer has increased in the urban population, with 1 in every 22 women diagnosed with breast cancer. It is important to know the HER2/neu gene status for a better prognostication of these patients. Aim :
Externí odkaz:
https://doaj.org/article/87fde82dfd1a40588a4d5cc890d69334
Autor:
Sananta Kumar Dash, Rajesh Chawla, Sudha Kansal, Devender Kumar Agrawal, Harsh Dua, Rakesh Sharma
Publikováno v:
Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine
Development of autoantibodies against coagulation factor VIII (FVIII) leads to a rare condition defined as acquired hemophilia (AH). If not diagnosed and treated early, AH may be associated with high mortality and morbidity. A 65-year-old woman prese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::029a9617e7a33aa1e99c6d62cad0d682
http://europepmc.org/articles/PMC3902575
http://europepmc.org/articles/PMC3902575
Publikováno v:
Apollo Medicine. 5:228-231
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8dea28ed1e9d000f8040194eefb0d157
https://doi.org/10.1016/s0976-0016(11)60492-4
https://doi.org/10.1016/s0976-0016(11)60492-4
Publikováno v:
The Journal of the Association of Physicians of India. 60
We report a 34 year old man who developed bilateral ptosis and predominantly respiratory, truncal and bulbar weakness, and a high titer of anti acetylcholine receptor antibodies along with a diagnosis of Philadelphia chromosome positive Chronic Myelo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b86c66f9e708f4147ccdad6b53cd057c
https://pubmed.ncbi.nlm.nih.gov/23405524
https://pubmed.ncbi.nlm.nih.gov/23405524
Autor:
Ramesh Sarin, Priyanka Srivastava, Mohit Chowdhry, Richa Tyagi, Raj Nath Makroo, Puja Das, Preeti Bhadauria, Manoj Kumar, Sumaid Kaul, Harsh Dua
Publikováno v:
Indian Journal of Pathology and Microbiology, Vol 55, Iss 4, Pp 481-484 (2012)
Background : In India, the incidence of breast cancer has increased in the urban population, with 1 in every 22 women diagnosed with breast cancer. It is important to know the HER2/neu gene status for a better prognostication of these patients. Aim :
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1e7f9968c7f46e95468b741df11f142
https://doi.org/10.4103/0377-4929.107785
https://doi.org/10.4103/0377-4929.107785
Autor:
Manas Kalra, Jyotishankar Raychaudhuri, Harsh Dua, Rashmi Thakur, Rakesh Chopra, Sangeeta Rawat, Mudhasir Ahmad
Publikováno v:
Blood. 116:4345-4345
Abstract 4345 We report the excellent tolerability of a regimen of HyperCVAD+Bortezomib for relapsed/refractory ALL in adults. The regimen consisted of addition of two doses of Bortezomib 2 mg(1mg/m2) on day 1 and day 4 of the HyperCVAD regimen(arm A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bee76e8db3f6312350d79d183bd5008
https://doi.org/10.1182/blood.v116.21.4345.4345
https://doi.org/10.1182/blood.v116.21.4345.4345